US20030065002A1 - Abuse-resistant controlled-release opioid dosage form - Google Patents

Abuse-resistant controlled-release opioid dosage form Download PDF

Info

Publication number
US20030065002A1
US20030065002A1 US10/143,111 US14311102A US2003065002A1 US 20030065002 A1 US20030065002 A1 US 20030065002A1 US 14311102 A US14311102 A US 14311102A US 2003065002 A1 US2003065002 A1 US 2003065002A1
Authority
US
United States
Prior art keywords
opioid
antagonist
pharmaceutical composition
composition according
naloxone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/143,111
Inventor
Frank Caruso
Huai-Hung Kao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29043901P priority Critical
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Priority to US10/143,111 priority patent/US20030065002A1/en
Assigned to ENDO PHARMACEUTICALS, INC. reassignment ENDO PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARUSO, FRANK S., KAO, HUAI-HUNG
Publication of US20030065002A1 publication Critical patent/US20030065002A1/en
Assigned to PURDUE PHARMA reassignment PURDUE PHARMA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ENDO PHARMACEUTICALS INC.
Assigned to PURDUE PHARMA L.P. reassignment PURDUE PHARMA L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PURDUE PHARMA
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.

Description

  • This application claims benefit of priority to U.S. Provisional Application No. 60/290,439 filed on May 11, 2001.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to controlled-release analgesic pharmaceutical formulations. More specifically, the invention relates to abuse-deterring controlled-release analgesic tablets. [0002]
  • BACKGROUND OF THE RELATED ART
  • Opioid compounds have long been known both for their powerful analgesic properties, and for their strong potential for abuse. While highly effective at controlling pain, opioids can also be addictive. Abuse of opioids, particularly heroin, but also including morphine, codeine, oxycodone, hydromorphone, oxymorphone, and others, is a problem in modem society. Opioid addicts can obtain drugs from a variety of illicit sources. These street drugs are of questionable quality. Therefore, to potential abusers, prescription pharmaceutical opioids can be particularly attractive as a drug source because of their high purity and dependable dosage. [0003]
  • Abusers extract the pharmaceutical opioid, and other constituents, from the tablets. To do so, the tablets are crushed and often dissolved. The result may be further treated before it is ultimately injected or snorted to achieve a “high”. This type of intravenous or intranasal abuse is well documented. [0004]
  • The potential for abuse of pharmaceutical opioids is not a new problem. To combat the effects of opioid abuse, opioid antagonists have been used to block the euphoria associated with opioid abuse, and to induce withdrawal symptoms in addicts. One opioid antagonist used previously, and even now, is naloxone. Naloxone is a powerful antagonist of the opioid receptor. Naloxone is highly effective when taken parenterally, but poorly effective when taken orally because of its metabolism in the liver and, thus, has a high oral:parenteral potency ratio. When injected in humans, amounts as small as 0.2-0.4 mg can block the opioid receptors and prevent the user from experiencing the drug's effects, whether analgesia or mood alteration, euphoria. Because of the high oral:parenteral potency ratio (˜100) the antagonist action of oral doses of naloxone is much lower than the action of injections of naloxone. Because antagonists such as naloxone are less effective when taken orally, they have not been used to deter oral abuse and have been limited to deterring parenteral or intranasal abuse. [0005]
  • Recently however, a new form of abuse of opioid agonists has emerged involving oral abuse instead of abuse by injection or snorting. This practice has emerged largely because of the availability of high-opioid content controlled release (CR) formulations. “Chewing” involves crushing the opioid formulation and taking the entire contents, meant for 2 or more doses, at once. This practice releases all the opioid at once to generate a “high.” The crushing may take place in the mouth as suggested by the name, but also may occur by other means to make the opioid readily available including, crushing or dissolving the tablet prior to injection or administered intransally. [0006]
  • Recently, high potency prescription opioid tablets containing large milligram doses of opioids have been introduced. These tablets are controlled release tablets and are designed to provide pain relief for 12 hours or more. Because the tablets have action over a long time period (12 hours instead of 4 hours for immediate release tablets), the tablets contain much higher quantities of opioid compounds. For potential abusers, these tablets are very attractive. Their high dosages make them a compact way to access large amounts of opioid. The fact that they are pharmaceuticals guarantees both the quality and quantity of drug in the tablet. Thus, the potential abuser knows he or she is obtaining a high purity drug in a known dosage. Prior oral opioid dosage formulations contained relatively low doses of opioid and were not generally targets for oral abuse. Their immediate release formulations release the opioid all at once, but with low amounts of opioid that would not be sufficient for oral abuse without putting several low dosage units together. In contrast, abusers have found that the new CR tablets contain large doses of opioid, which can be abused orally by chewing the tablets or crushing them to release all of the opioid at one time (immediate release). The present invention deters such oral abuse. [0007]
  • Oxycontin®, a controlled release oxycodone tablet from Purdue Pharma, is available in strengths as high as 160 mg oxycodone per tablet. The high opioid content makes these tablets especially attractive to abusers. Illegal trade in controlled release opioid tablets is becoming more prevalent. In order to obtain a euphoric effect (high) from such tablets, an abuser may crush the tablet and extract the opioid compound by dissolution for injection, or intranasal administration. Also, the abuser can achieve a euphoric effect from the drug by simply taking the drug orally, after chewing the tablet or grinding it to break the controlled release matrix and converting it to an immediate release product. Therefore, it would be desirable to have a formulation which would prevent the oral abuse of controlled release tablets if crushed to convert it to an immediate release product, without significantly affecting the analgesic action of opioid compounds in the intact controlled release tablet. [0008]
  • WO 01/58447 discloses pharmaceutical combinations of opioid agonists and antagonists in a controlled release matrix. The antagonist is present and released in amounts, over time, that attenuate or reduce the side effects of the opioid agonist, yet in amounts insufficient to block the opioid effect. The preferred antagonist is Naltrexone, which is highly effective when administered orally or parenterally. The antagonist is released only in very small amounts, 100-1000 times less than the opioid. WO '447 is silent with respect to including an anti-abusive amount of antagonist in the dose to prevent abuse. The intravenous use of small amounts of naloxone, 0.25 or 1 μg kg[0009] −1hr−1, is also disclosed as having attenuating effects.
  • WO '447 does not present release rates for the antagonist in its CR formulation, but directs those skilled in the art to the Crain patents (U.S. Pat. Nos. 5,767,125; 5,580,876; 5,512,578; and 5,472,943). The Crain patents collectively disclose instant release formulations with “ultra-low” doses of certain antagonists to selectively block only the excitatory opioid receptors to attenuate opioid side effects, without blocking inhibitory receptors, which would lead to opioid blocking. These doses are on the order of pico-molar amounts. Crain '578 suggests that only naltrexone is useful in oral administration and that 1 μg doses are sufficient for attenuating opioid side effects by selectively blocking the excitatory opioid receptors and leaving the inhibitory opioid receptors free for receiving the opioid agonist (which may be administered in lower than normal doses with similar analgesic effect). The normal oral dose of naltrexone is about 50 mg versus “ultra low” does of 1 μg of naltrexone described in Crain '578 patent. [0010]
  • The prior art does not discuss controlled release formulation containing agonist and antagonist to deter abuse. Accordingly, there is a need for a composition that deters abuse in the high opioid-content controlled release formulation prevalent today. [0011]
  • SUMMARY OF THE INVENTION
  • Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist having a high oral:parenteral potency ratio (i.e. oral:parenteral>1), such as naloxone, at a level insufficient to block the opioid effects or to attenuate the opioid side-effects in the controlled release formulation administered over an extended period, but above that needed to suppress the euphoric effect of the opioid if administered all at once. If the combination tablet is crushed to break the controlled release properties, the opioid and opioid antagonist is released as an immediate release product in a single dose, and the antagonist blocks the euphoric effects of the agonist. The opioid antagonist is contained in a controlled-release matrix and released over time, with the opioid agonist.[0012]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention employs the principle that certain opioid antagonists are ineffective in low oral doses. Therefore, one can administer a low oral dose over a long period of time (controlled release) from a tablet containing a large, orally effective amount of antagonist, without adversely affecting the action of the opioid. However, if the antagonist is administered all at once, it will block the opioid effect and may induce withdrawal in dependent individuals. [0013]
  • The present invention is intended for use in controlled release compositions. The term, “controlled release” or “CR” when used herein, is intended to refer to tablets intended to release an active pharmaceutical ingredient over an extended period of time, usually over 4 hours, generally 8-12 or up to 24 hours. One method of determining this is to check the intended dosing schedule. Any tablet intended to be taken less frequently than once every four hours should be considered controlled release regardless of labeling as controlled release, sustained release, extended release, etc. Often, these tablets contain polymeric matrices which may be cross-linked. Examples of such controlled release formulations are the Contin® system, produced by Purdue Fredrick Pharmaceuticals, or the TimerX® system by Pennwest Pharmaceuticals. Other controlled release polymers can also be used, such as methacrylate (Eudragit®), hydroxylpropyl methylcellulose (HPMC), or Carbopol®. The present invention may be used with these or other controlled release formulations. [0014]
  • The tablet of the present invention contains an opioid agonist in a controlled release matrix, along with an opioid antagonist. The antagonist is present at such a level, and dispensed at such a rate, that it will not block the action of the opioid agonist when an intact controlled release tablet is taken orally. Crushing the tablet will release sufficient antagonist all at once as an immediate release formulation to block the opioid response and also, induce abstinence. Antagonists need to reach an effective dose to work, so their slow release coupled with fast metabolism means they are maintained at ineffective, low levels in normal, recommended, therapeutic, non-abusive use. This low level of antagonist can be released over a long time period without affecting the therapeutic action of the opioid agonist. Even with sustained release over such long periods, the antagonist does not accumulate to blocking levels, since it is metabolized before it can accumulate to such levels. Because of the nature of the opioid antagonist action, the level of antagonist should be varied with the opioid dosage of the tablet. Also, depending on the antagonist, the oral:parenteral potency ratio, and the release rates, the levels of antagonists employed will vary. Regardless, there should be sufficient antagonist to block the opioid effect (high) and induce withdrawal in dependent individuals, if the tablet is crushed, converting the formulation to immediate release. Under normal conditions, the release rate is not sufficient for blocking the opioid effect nor suitable for selectively blocking the excitatory opioid receptors to attenuate opioid side effects. For Naloxone, the presently preferred antagonist, it is believed that 15 mg (immediate release) should begin to block the opioid receptors and initiate withdrawal. [0015]
  • The specific opioid agonists, antagonists, CR matrices, and the combinations disclosed herein are merely exemplary. Other agonists, antagonists, matrices, and combinations may be used in conjunction with the teachings herein. [0016]
  • The opioid agonist can be any agonist in general use as an analgesic, including, but not limited to, morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone. Specifically, any addictive opioid in a controlled release dosage form is the target of the present invention. Most particularly, controlled release oxycodone has recently been the target of abuse, and would therefore make a good candidate for use in the present invention. Of course, the release rate of the opioid agonist is established to achieve the desired analgesic effect. [0017]
  • Potency of the antagonist is measured as the oral:parenteral potency ratio, which indicates the amount of antagonist required orally to achieve an equivalent effect to an effective parenteral dose. For example, an antagonist having an oral:parenteral potency ratio of 10:1 requires 10 times the parenteral dose to be effective orally. The opioid antagonists used herein will have greater antagonistic effect when administered parenterally than when administered orally (oral:parenteral potency ratio>1). Accordingly, the desired antagonists block the opioid effect and induce withdrawal when administered at relatively low levels parenterally or intranasally. At the same time, these antagonists require relatively large levels to be effective when administered orally for recommended, therapeutic use. Thus, effective parenteral/intranasal doses are ineffective when administered orally. Preferably, the oral:parenteral potency ratio is at least approximately 10:1, more preferably at least approximately 25:1, and most preferably at least approximately 100:1 as is the case with Naloxone. Appropriate opioid antagonists having substantially greater effectiveness when administered by injection than when administered orally, include, but are not limited to: naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone or 21 cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or diphenorphine); and the pharmaceutically-acceptable salts thereof. [0018]
  • It has previously been known that opioid antagonists, such as naloxone, can block opioid receptors and reduce or eliminate the effect of opioids. Such antagonists are useful in treating opioid overdoses and to help treat addiction, in some cases. By blocking opioid receptors, the antagonists reverse and block the response to opioids. The high oral:parenteral potency ratio antagonists, such as naloxone, while very effective when injected, are significantly less effective when taken orally. Therefore, a dosage form designed for oral administration can have a significant amount of opioid antagonist, without adversely affecting the therapeutic efficacy of the opioid. Similarly, these levels of antagonists do not attenuate the side effects of the opioid. Such an antagonist would be effective in deterring intravenous or intranasal abuse when present in low levels, but would be ineffective in deterring oral abuse. Were the tablets to include sufficient antagonist to deter oral abuse, the antagonist would also reduce or inhibit the therapeutic efficacy of the drug. A tablet containing an orally effective amount of antagonists in a CR formulation releasing ineffective amounts of antagonist under normal use would be effective against both oral and parenteral abuse, without minimizing the effectiveness of the opioid under normal use. [0019]
  • The amount of antagonist in the composition will depend on the relative strength of the antagonist, the amount and strength of the opioid, the release rate of the antagonist, and the oral:parenteral potency ratio. In any event, the combination of antagonist type, oral:parenteral potency ratio, quantity, and release rate do not result in blockage of the opioid effect or attenuation of its side effects, when administered orally in its intended, intact dosage form. [0020]
  • Strengths of controlled release opioid tablets vary with the particular opioid used. In the case of oxycodone, strengths of 10, 20, 40, 80, and 160 mg may be used in a controlled release formula. The amount of opioid antagonist (such as naloxone) in such a tablet may also vary from about 2 mg to 40 mg or more. There should be at least 5 to 20 mg (preferably 10 to 20 mg) of naloxone in a tablet to prevent oral abuse by chewing a number of small, low dose tablets or a higher strength tablet. That is, the accumulation of an abusive dose by combining 2 or more low-dose tablets should also accumulate an effective amount of antagonist. Higher dose opioid tablets should contain an effective amount of antagonist without accumulation. Prevention of abuse by parenteral or intranasal administration will also be accomplished, since in the case of injection or snorting, only about 0.2 to 0.4 mg naloxone is needed to antagonize the opioid effect, to induce abstinence in dependent individuals, and to prevent abuse. Therefore the larger amount needed to prevent oral abuse will necessarily prevent abuse by injection or intranasal administration as well. [0021]
  • For oxycodone tablets of 10 or 20 mg tablet strength, the amount of naloxone, opioid antagonist used can range from 5 to 40 mg. As the tablet strength rises, the ratio of opioid to opioid antagonist varies from 1:3 to 4:1, since a 160 mg opioid tablet may contain 80 mg opioid antagonist. Although the ratio can vary, it is preferable to select one ratio for all tablet strengths. Physicians prefer to titrate patients using several low dose tablets which add up to the desired dosage. This is easiest if a constant ratio is maintained. Thus, a constant ratio across tablet strengths is useful even though that ratio can be any appropriate ratio in the range set forth above. [0022]
  • Drug abusers are creative when finding ways to defeat anti-abusive measures. Currently, several methods of oral abuse are contemplated. As discussed above, it should be remembered that the compositions of the invention contain sufficient antagonist to be effective orally and, therefore, necessarily contain a parenterally or intranasally effective blocking amount. Accordingly, parenteral and intranasal abuse are not discussed here. [0023]
  • Abusers may “chew” a single large dose tablet to achieve instant release of an abusive dose of opioid. Compositions containing these abusive amounts of opioid should contain enough antagonist to block oral abuse by “chewing.”[0024]
  • Two or more lower dose tablets may be “chewed” together to achieve an abusive dose. To the extent that each tablet itself does not contain an orally, effective amount of antagonist, when combined to an abusive dose, the combined antagonist should be orally effective. That is if, for example, a 10 mg tablet is not sufficient to achieve a high, it need not contain the full orally effective amount of antagonist. If two 10 mg tablets are sufficient for a high, they then should contain a combined amount of antagonist which is effective orally for blocking the opioid effect. [0025]
  • Additionally, two or more high-dose tablets could be taken orally, without crushing, to achieve a “high.” Such a combination would take advantage of the CR properties to sustain a high for the entire dosage period up to 12 hours. This type of abuse is uncommon since most abusers want the instant high or rush afforded by the immediate release of the crushed tablets. Such a combination, according to one embodiment of the invention, should also release a blocking amount of antagonist when taken orally without chewing. This arrangement would also prevent the dire effects of accidental overdose. Although this type of arrangement would be beneficial in many situations, it could limit a prescribing doctor's options, and therefore, may not be appropriate in all situations. Tablets according to this embodiment are not preferred, but are certainly within the scope of the invention. [0026]
  • Tablets according to the invention may take into consideration any of the above abusive regimes individually or any combination thereof. [0027]
  • The basic underlying premise of the invention is that the tablet contains 1) an amount of antagonist which is orally effective for blocking the opioid effect and 2) that the antagonist is available, normally, only at levels that are ineffective to block the opioid effect or to attenuate the opioid side-effects. One of the ways to achieve this is to control the release rate of the antagonist. The release rate of the antagonist is best thought of in terms of a percent of the release rate of the opioid agonist. The rate is controlled between approximately 100%-0% of the release rate of the opioid, preferably 100%-25%. Table 1 shows release rates of opioid and antagonist as % released. In the case of 0%, the antagonist is never released unless the tablet is crushed. But, that is the subject of another application. [0028]
  • In the case of Naloxone, the short half-life (about one hour) ensures that the Naloxone does not accumulate to blocking levels, even when released at the same rate as the opioid. In slower release formulations (50% and 75%), the unreleased portion remaining after 10-12 hours passes to the large intestine where the absorption rate is much slower than in the stomach and small intestine. Accordingly, the amount of antagonist released beyond 10-12 hours does not contribute to any blocking or attenuating effect. [0029]
  • These release rates ensure that under normal usage the antagonist has no blocking or attenuating effect. Simultaneously, however, an orally effective blocking dose of the antagonist is present in the event that the CR properties are defeated. [0030]
  • The type and application of CR matrix used will determine release rates. Manipulation of release rates, even of two compounds with two different rates is—known in the art. Any known or later developed CR techniques may be used. It is important to remember though, that the antagonist should not be readily distinguishable or separable from the agonist, since would be abusers could possibly use mechanical separation techniques prior to defeating the CR formulation. [0031]
    TABLE 1
    Release Rates from CR formulation
    ANTAGONIST
    (as % of AGONIST release rate)
    AGONIST 100% 50% 25%
     1 HR 20-30% 20-30% 10-15% 5-7.5%
     4 HRS 60-70% 60-70% 30-35% 15-17.5%
    10 HRS >90% >90% 45-50% 22.5-25%   
  • Release rates are a percentage of agonist or antagonist with respect to its total content in the composition. [0032]
  • The tablets may be made by any traditional method of manufacture of controlled release tablets. Two principal processes are wet process (including wet granulation) and dry process (including direct mixing and roller compaction process.) Exemplary compositions for those processes are reproduced below. [0033]
    TABLE 2
    Preferred Naloxone Ranges for Differing Strengths of Oxycodone Tablets
    Oxycodone (mg) 10 20 40 80 160
    Naloxone (mg) 2-10 4-20 8-40 16-80 20-160
  • For oxymorphone, the doses for controlled release tablets may be 10, 20, or 40 mg and the naloxone dose ranges may be the same as set forth for oxycodone. [0034]
  • The preferred oxycodone:naloxone ratio is 5:1 to 1:1. [0035]
    TABLE 3
    Formula 1 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 2.22%
    Naloxone 10.00 2.22%
    Lactose (spray-dried) 281.50 62.56%
    Hydroxypropyl Methylcellulose, 135.00 30.00%
    K100M
    Silicone Dioxide 9.00 2.00%
    Magnesium Stearate 4.50 1.00%
    Total: 450.00 100.00%
  • [0036]
    TABLE 4
    Formula 2 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 3.77%
    Naloxone 10.00 3.77%
    Lactose (spray-dried) 157.55 59.45%
    Hydroxypropyl Methylcellulose, 79.50 30.00%
    K100M
    Silicone Dioxide 5.30 2.00%
    Magnesium Stearate 2.65 1.00%
    Total: 265.00 100.00%
  • [0037]
    TABLE 5
    Formula 3 of Oxycodone HCl 10-mg Tablets with Naloxone
    Component mg/Tablet percent (by wt)
    Oxycodone Hydrochloride 10.00 8.33%
    Naloxone 10.00 8.33%
    Lactose (spray-dried) 60.40 50.33%
    Hydroxypropyl Methylcellulose, 36.00 30.00%
    K100M
    Silicone Dioxide 2.40 2.00%
    Magnesium Stearate 1.20 1.00%
    Total: 120.00 100.00%
  • Alternate compositions may also be used. Preferably, tablets according to the present invention will have the following compositions: [0038]
    Material Quantity (%)
    Oxycodone Hydrochloride, USP  2.000-35.000
    Naloxone  2.000-20.000
    Microcrystalline Cellulose, NF (Avicel PH102) 10.000-50.000
    Ammonio Methacrylate Copolymer, NF (Eudragit RSPO) 30.000-70.000
    Colloidal Silicon Dioxide, NF (Cab-O-Sil)    0-5.000
    Sodium Lauryl Sulfate, NF    0-5.000
    Magnesium Hydroxide, USP    0-2.000
    Povidone, USP    0-15.000
    Stearic Acid, NF    0-5.000
    Magnesium Stearate, NF    0-5.000
  • Dissolution was conducted according to USP XXIV Apparatus 3 (Reciprocating Cylinder) for Formulation 1-3. The apparatus 3 is to simulate the gastrointestinal conditions of human. The 1 st hour is at pH 1.2 of 0.1N HCl. The 2nd and 3rd hours are at pH 4.5 of 10 mM of potassium phosphate monobasic. The conditions after the 3[0039] rd hours are at pH 6.8 of 10 mM of potassium phosphate monobasic. All dissolution vessels contain 250 mL of dissolution solution. The dip rate is set at 10 dips per minute. The bath temperature is set at 37.5° C. The HPLC parameters are set as follows: Column—Inertsil ODS 3, 50 mm×4.6 mm, 3 μm particle size. Mobile phase: 80% 30 mM sodium hexanesulfonate pH 3.0+/−1, 20% acetonitrile. Injection volume is 75 μL. Column temperature is 35° C., Flow rate is set at 1.0 mL/min. Wavelength is set at 225 nm. Run time is 5.5 minutes.
  • Dissolution results for Formulation 1-3 were as follows: [0040]
    Formulation 1
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 29.8 27.8 88.2 94.6
    2 47.8 45.4
    3 59.8 57.4
    4 68.5 65.9
    8 91.1 87.5
    12 100.7 97.9
  • [0041]
    Formulation 2
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 40.1 37.0 104.9 102.8
    2 63.2 60.3
    3 77.3 75.3
    4 86.5 85.2
    8 105.6 106.1
    12 110.5 112.6
  • [0042]
    Formulation 3
    Tablet not Crushed Tablet Crushed
    % Oxycodone % Naloxone % Oxycodone % Naloxone
    Time Dissolved Dissolved Dissolved Dissolved
    0 0.0 0.0 0.0 0.0
    1 59.0 52.5 100.5 90.9
    2 85.4 78.0
    3 97.4 90.3
    4 102.5 95.9
    8 105.4 99.7
    12 105.4 99.8
  • From these tests, it is evident that under normal, non-crushing use, the amount of antagonist, here naloxone, released over time is insufficient to block the opioid effect. Even Example 3 which has the highest initial release rate of antagonist, only makes about 5 mg naloxone available in the first hour. Due to the short half-life of naloxone, and the slow release rate, the antagonist does not accumulate in the body to a level that blocks the opioid effect. On the other hand, in the crushed tablet, substantially all of the antagonist is available in the first hour. Thus, an opioid blocking amount of antagonist is readily available to deter oral and other forms of abuse. Regardless of the antagonist used, the combination of the antagonist content, the release rate, and the antagonist half-life achieves the goals of the invention to block the opioid effect when administered as for instant release, yet not blocking the opioid effect when administered as intended and recommended as a controlled release formulation. [0043]
  • It is well known that the various opioids have differing relative strengths. Often, these are compared and related to a standard for determining relative doses of each. Although this application discusses opioid content in terms of oxycodone, those skilled in the art will readily appreciate that other opioids, stronger and weaker, can be used in equivalent dosage amounts. Likewise, the antagonist is similarly selected and dosed. [0044]
  • The scope of the invention is not limited to the above examples, which are provided only for purposes of illustration. The above description is written in the context of a tablet. Other oral dosage forms, capable of being made in CR formulations may be used. Among the oral dosage forms available are capsules, caplets, microspheres, gel caps and even liquid formulations. [0045]

Claims (20)

What is claimed is:
1. An oral pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an orally effective amount for blocking the opioid effect and/or inducing withdrawal when the controlled release matrix is defeated and the composition improperly administered for immediate release;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
2. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 to approximately 25 percent of the release rate of the opioid agonist.
3. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 percent of the release rate of the opioid agonist.
4. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 50 percent of the release rate of the opioid agonist.
5. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 25 percent of the release rate of the opioid agonist.
6. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 10:1.
7. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 25:1.
8. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 100:1.
9. The pharmaceutical composition according to claim 1, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone.
10. The pharmaceutical composition according to claim 1 wherein the opioid antagonist is selected from the group consisting of naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone; and 21-cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or diphenorphine) and the pharmaceutically-acceptable salts thereof.
11. The pharmaceutical composition according to claim 1 wherein said opioid antagonist is naloxone.
12. The pharmaceutical composition according to claim 1 wherein said opioid agonist is oxycodone.
13. The pharmaceutical composition according to claim 1 wherein said opioid agonist is present in concentration pharmaceutically equivalent to oxycodone doses of approximately 10-160 mg.
14. The pharmaceutical composition according to claim 1, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined—with or without crushing—to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
15. A pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an amount proportional to the number of abusive doses of the opioid agonist in the composition such that if the CR matrix is defeated and two or more doses of the composition are combined to yield an abusive dose of the opioid agonist, the amount of opioid antagonist will suffice to block the opioid effect and/or induce withdrawal when taken orally;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking the inhibitory and excitatory receptors or attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
16. The pharmaceutical composition according to claim 15, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined—with or without crushing—to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
17. An oral pharmaceutical composition comprising:
a controlled release matrix;
approximately 10-160 mg oxycodone;
approximately 2-160 mg naloxone;
wherein the ratio of oxycodone to naloxone is approximately 4-5:1 to 1:1;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the oxycodone for maintaining pharmaceutical effectiveness for a period up to 12 hours and for controlling the release rate of the naloxone such that naloxone levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
18. An oral pharmaceutical composition comprising, in % by weight:
about 3-35% opioid agonist;
about 2-20% opioid antagonist;
about 10-50% microcrystalline cellulose, NF;
about 30-70% ammonio methacrylate copolymer, NF; and
at least one excipient selected from the group consisting of:
up to about 5% colloidal silicon dioxide, NF;
up to about 5% sodium lauryl sulfate, NF;
up to about 2% magnesium hydroxide, USP;
up to about 15% povidone, USP;
up to about 5% stearic acid, NF; and
up to about 5% magnesium stearate, NF;
wherein said composition is a controlled release formulation adapted to release the oxycodone at a therapeutically effective rate, and to release said naloxone at a rate ineffective for blocking the opioid effect and/or inducing withdrawal when the controlled release formulation is taken orally in intact form.
19. The oral pharmaceutical composition according to claim 18, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone and the opioid antagonist is selected from the group consisting of naloxone; naltrexone; N-cyclo propylmethyl-7,8-dihydro-14-hydroxynormorphinone; and 21-cyclopropyl z, -(1-hydroxy-1-methylethyl)-6,14-endo-ethano-tetrahydrooripavine (or salts thereof.
20. The oral pharmaceutical composition according to claim 18 wherein said opioid agonist is oxycodone hydrochorlide and said opioid antagonist is naloxone.
US10/143,111 2001-05-11 2002-05-10 Abuse-resistant controlled-release opioid dosage form Abandoned US20030065002A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29043901P true 2001-05-11 2001-05-11
US10/143,111 US20030065002A1 (en) 2001-05-11 2002-05-10 Abuse-resistant controlled-release opioid dosage form

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US10/143,111 US20030065002A1 (en) 2001-05-11 2002-05-10 Abuse-resistant controlled-release opioid dosage form
US11/901,232 US20080069881A1 (en) 2001-05-11 2007-09-14 Abuse-resistant controlled-release opioid dosage form
US13/494,431 US20120252832A1 (en) 2001-05-11 2012-06-12 Abuse-resistant controlled-release opioid dosage form
US13/777,537 US20130172382A1 (en) 2001-05-11 2013-02-26 Abuse-resistant controlled-release opioid dosage form
US14/067,821 US9084729B2 (en) 2001-05-11 2013-10-30 Abuse-resistant controlled-release opioid dosage form
US14/136,443 US8969369B2 (en) 2001-05-11 2013-12-20 Abuse-resistant controlled-release opioid dosage form
US14/205,204 US9056051B2 (en) 2001-05-11 2014-03-11 Abuse-resistant controlled-release opioid dosage form
US14/725,369 US9161937B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/725,379 US9168252B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/859,195 US9283216B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US14/859,200 US9283221B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US15/014,995 US9358230B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/015,019 US9345701B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/159,737 US9480685B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/159,465 US9511066B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/280,621 US20170014406A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/280,541 US20170014405A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/898,018 US20180185353A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US15/898,069 US20180169090A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US16/222,720 US20190111051A1 (en) 2001-05-11 2018-12-17 Abuse-resistant controlled-release opioid dosage form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/901,232 Division US20080069881A1 (en) 2001-05-11 2007-09-14 Abuse-resistant controlled-release opioid dosage form

Publications (1)

Publication Number Publication Date
US20030065002A1 true US20030065002A1 (en) 2003-04-03

Family

ID=23116001

Family Applications (20)

Application Number Title Priority Date Filing Date
US10/143,111 Abandoned US20030065002A1 (en) 2001-05-11 2002-05-10 Abuse-resistant controlled-release opioid dosage form
US11/901,232 Abandoned US20080069881A1 (en) 2001-05-11 2007-09-14 Abuse-resistant controlled-release opioid dosage form
US13/494,431 Abandoned US20120252832A1 (en) 2001-05-11 2012-06-12 Abuse-resistant controlled-release opioid dosage form
US13/777,537 Abandoned US20130172382A1 (en) 2001-05-11 2013-02-26 Abuse-resistant controlled-release opioid dosage form
US14/067,821 Active US9084729B2 (en) 2001-05-11 2013-10-30 Abuse-resistant controlled-release opioid dosage form
US14/136,443 Active US8969369B2 (en) 2001-05-11 2013-12-20 Abuse-resistant controlled-release opioid dosage form
US14/205,204 Active US9056051B2 (en) 2001-05-11 2014-03-11 Abuse-resistant controlled-release opioid dosage form
US14/725,369 Active US9161937B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/725,379 Active US9168252B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/859,195 Active US9283216B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US14/859,200 Active US9283221B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US15/015,019 Active US9345701B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/014,995 Active US9358230B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/159,737 Active US9480685B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/159,465 Active US9511066B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/280,541 Abandoned US20170014405A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/280,621 Abandoned US20170014406A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/898,069 Abandoned US20180169090A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US15/898,018 Abandoned US20180185353A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US16/222,720 Pending US20190111051A1 (en) 2001-05-11 2018-12-17 Abuse-resistant controlled-release opioid dosage form

Family Applications After (19)

Application Number Title Priority Date Filing Date
US11/901,232 Abandoned US20080069881A1 (en) 2001-05-11 2007-09-14 Abuse-resistant controlled-release opioid dosage form
US13/494,431 Abandoned US20120252832A1 (en) 2001-05-11 2012-06-12 Abuse-resistant controlled-release opioid dosage form
US13/777,537 Abandoned US20130172382A1 (en) 2001-05-11 2013-02-26 Abuse-resistant controlled-release opioid dosage form
US14/067,821 Active US9084729B2 (en) 2001-05-11 2013-10-30 Abuse-resistant controlled-release opioid dosage form
US14/136,443 Active US8969369B2 (en) 2001-05-11 2013-12-20 Abuse-resistant controlled-release opioid dosage form
US14/205,204 Active US9056051B2 (en) 2001-05-11 2014-03-11 Abuse-resistant controlled-release opioid dosage form
US14/725,369 Active US9161937B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/725,379 Active US9168252B2 (en) 2001-05-11 2015-05-29 Abuse-resistant controlled-release opioid dosage form
US14/859,195 Active US9283216B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US14/859,200 Active US9283221B2 (en) 2001-05-11 2015-09-18 Abuse-resistant controlled-release opioid dosage form
US15/015,019 Active US9345701B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/014,995 Active US9358230B1 (en) 2001-05-11 2016-02-03 Abuse-resistant controlled-release opioid dosage form
US15/159,737 Active US9480685B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/159,465 Active US9511066B2 (en) 2001-05-11 2016-05-19 Abuse-resistant controlled-release opioid dosage form
US15/280,541 Abandoned US20170014405A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/280,621 Abandoned US20170014406A1 (en) 2001-05-11 2016-09-29 Abuse-resistant controlled-release opioid dosage form
US15/898,069 Abandoned US20180169090A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US15/898,018 Abandoned US20180185353A1 (en) 2001-05-11 2018-02-15 Abuse-resistant controlled-release opioid dosage form
US16/222,720 Pending US20190111051A1 (en) 2001-05-11 2018-12-17 Abuse-resistant controlled-release opioid dosage form

Country Status (10)

Country Link
US (20) US20030065002A1 (en)
EP (1) EP1387673B1 (en)
JP (7) JP4522652B2 (en)
CN (1) CN1525851A (en)
AT (1) AT493130T (en)
AU (2) AU2002305559B2 (en)
CA (1) CA2446550C (en)
DE (1) DE60238756D1 (en)
ES (1) ES2361148T3 (en)
WO (1) WO2002092060A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US20030129230A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US20040131552A1 (en) * 2002-09-20 2004-07-08 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US20060104909A1 (en) * 2002-09-23 2006-05-18 Farid Vaghefi Abuse-resistant pharmaceutical compositions
US20060130828A1 (en) * 2004-12-20 2006-06-22 Sexton Douglas A Method for making a pharmaceutically active ingredient abuse-prevention device
US20060198881A1 (en) * 2003-04-30 2006-09-07 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20070098794A1 (en) * 2001-07-06 2007-05-03 Haui-Hung Kao Oxymorphone controlled release formulations
US20070134328A1 (en) * 2001-07-06 2007-06-14 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US20070185147A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070207089A1 (en) * 2004-03-30 2007-09-06 Osvaldo Abreu Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080233197A1 (en) * 2006-06-19 2008-09-25 Francis Joseph Matthews Pharmaceutical compositions
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090175937A1 (en) * 2007-12-17 2009-07-09 Labopharm, Inc. Misuse Preventative, Controlled Release Formulation
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100239662A1 (en) * 2008-12-16 2010-09-23 Miloud Rahmouni Misuse preventative, controlled release formulation
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110135731A1 (en) * 2001-05-11 2011-06-09 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
US20110237615A1 (en) * 2008-12-12 2011-09-29 Paladin Labs Inc. Narcotic Drug Formulations with Decreased Abuse Potential
US20120183612A1 (en) * 2002-04-05 2012-07-19 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20120225901A1 (en) * 2005-02-28 2012-09-06 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
WO2015066172A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151057D0 (en) * 2000-02-08 2003-04-10 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
DK1436012T3 (en) 2001-10-18 2018-01-22 Nektar Therapeutics Polymer conjugates of opioid antagonists
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
GB0506982D0 (en) * 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
BRPI0619806A2 (en) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc Supply device for transmucosal drug abuse resistant
EP1810678A1 (en) 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
CN103550136B (en) 2006-07-21 2016-04-13 生物递送科学国际公司 Transmucosal absorption enhancement of the delivery device
DE202006018609U1 (en) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids
WO2008068471A1 (en) 2006-12-04 2008-06-12 Orexo Ab New non-abusable pharmaceutical composition comprising opioids
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
CA2767888C (en) 2009-07-22 2017-09-12 Gruenenthal Gmbh Tamper-resistant dosage form for oxidation-sensitive opioids
PE10672012A1 (en) 2009-07-22 2012-09-05 Gruenenthal Chemie Form of controlled release dosage extruded by hot melt
CN103002881B (en) 2010-05-10 2015-09-02 欧洲凯尔特公司 Compositions containing the active agent particles and the additional active agent
EP2568967B1 (en) * 2010-05-10 2018-10-24 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012028788A2 (en) 2010-05-10 2016-07-19 Euro Celtique Sa manufacturing granules without active
JP5933553B2 (en) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Abuse-resistant dosage form comprising an anionic polymer
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
BR112014006356A2 (en) 2011-09-19 2017-04-04 Orexo Ab new pharmaceutical composition resistant to abuse for the treatment of opioid dependence
AR088875A1 (en) * 2011-11-17 2014-07-16 Grünenthal GmbH Oral pharmaceutical dosage form of tamperproof
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US8946253B2 (en) 2012-04-17 2015-02-03 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20150045383A1 (en) 2012-07-31 2015-02-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Modified anti containing one or more particles (tamper-resistant) dosage forms
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Containing tapentadol, modified prevent immediate release capsule formulation
MX2016015417A (en) 2014-05-26 2017-02-22 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping.
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediately released and prevent the tamper-resistant dosage form extraction solvent

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6387404B2 (en) * 1993-11-23 2002-05-14 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations

Family Cites Families (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (en) 1960-11-29
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (en) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
FR2183546B1 (en) 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3966040A (en) 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
LU77339A1 (en) * 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
ZA8200490B (en) * 1981-02-12 1983-09-28 Wyeth John & Brother Ltd Treating shock
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JPH045647B2 (en) 1982-03-16 1992-02-03 Univ Rockefeller
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
DE3434946A1 (en) 1984-09-22 1986-04-03 Basf Ag Diarylacetylenes, their production and use
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
ZA8601211B (en) 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (en) 1985-07-26 1987-01-30 Cortial Method for producing solid dosage forms has sustained release
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
JPS63500799A (en) 1985-09-06 1988-03-24
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3750145D1 (en) 1986-06-10 1994-08-04 Euro Celtique Sa The controlled release composition of dihydrocodeine.
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag A process for preparing pharmaceutical mixtures
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (en) 1990-11-20 1993-01-22 Adir New derivatives oxazolo pyridines, their preparation processes and pharmaceutical compositions containing them.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (en) 1991-05-29 2001-06-18 キヤノン株式会社 Image processing method and apparatus
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
KR100221695B1 (en) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 Pharmaceutical spheroid formulation
GB9117361D0 (en) 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100243956B1 (en) 1991-09-06 2000-03-02 랄프 알. 팔로 Composition comprising a tramadol material and actaminophen for the treatment of pain
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
DE69334237D1 (en) 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycine receptor antagonists and their use
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
JPH08504189A (en) 1992-09-21 1996-05-07 ウォン、チャン・イ The method of confirmation and use low / non-addictive opioid analgesic
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US5849240A (en) 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
DE69429710D1 (en) 1993-11-23 2002-03-14 Euro Celtique Sa A process for preparing a pharmaceutical composition having sustained-release
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (en) 1993-07-29 2004-03-04 Jurna, Ilmar, Prof. Dr.med. An oral pharmaceutical composition for the treatment of pain
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
HU218673B (en) 1993-10-07 2000-10-28 Euroceltique S.A. Controlled release pharmaceutical composition for orally administration comprising opioid analgesic and process for producing its
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP2301562B1 (en) 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
BE1009257A3 (en) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Pharmaceutical matrix.
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
JP2897964B2 (en) 1995-06-09 1999-05-31 ユーロ−セルティーク,エス.エイ. Formulations and methods for applying the local anesthetic in sustained
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
WO1997020819A1 (en) 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
AU2059297A (en) 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
DE19651551C2 (en) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing pharmaceutical formulation
DE29719704U1 (en) 1997-02-14 1998-01-22 Goedecke Ag Stable preparations of naloxone hydrochloride
WO1998035679A1 (en) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilization of naloxonhydrochlorid
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (en) 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase preparation forms of an opioid sustained release Analgeticums
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
AU3690297A (en) 1997-07-30 1999-02-22 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
EP1327447B1 (en) 1997-09-04 2011-05-25 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
AT210983T (en) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilized combination product containing naloxone and an opiate analgesic
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU747751B2 (en) 1998-03-27 2002-05-23 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
DE19857766A1 (en) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Retarded painkillers containing tilidine
SE9803760D0 (en) 1998-11-04 1998-11-04 Jan Hedner Ways to treat and diagnose restless legs syndrome and matching funds
FR2787715B1 (en) 1998-12-23 2002-05-10 Synthelabo A pharmaceutical composition comprising a hypnotic compound or a pharmaceutically acceptable salt thereof
DE19859636A1 (en) 1998-12-23 2000-06-29 Hexal Ag A controlled-release pharmaceutical composition containing Tilidine Mesylate as an active ingredient
DE19901085C2 (en) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermal therapeutic system with a self-adhesive matrix containing organic acid addition salts of morphine alkaloids of the or Morphinantyps
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
AU2001259560B2 (en) 2000-05-05 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
US20030178031A1 (en) 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6451007B1 (en) * 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (en) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
US6258042B1 (en) 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
AU776567B2 (en) 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
ES2278647T3 (en) 1999-11-29 2007-08-16 Adolor Corporation New methods and compositions comprising opioids and opioid antagonists.
JP2001174985A (en) * 1999-12-15 2001-06-29 Sumitomo Chem Co Ltd Pigment dispersed photosensitive fluid, method for producing same and colored image forming method using same
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE60119696T2 (en) 2000-03-15 2007-01-25 Wolfgang Ross Sadee Naloxone and naltrexone analogs drug abuse in the treatment at
EP1284736A2 (en) 2000-05-05 2003-02-26 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist compositions and dosage forms
JP2003535833A (en) 2000-06-09 2003-12-02 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Method for the treatment of pain using nalbuphine and opioid antagonist
US7223421B2 (en) 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR031152A1 (en) 2000-10-31 2003-09-10 Upjohn Co new treatments for restless leg syndrome
CA2444053C (en) 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
AU2002303614B2 (en) 2001-05-02 2005-02-10 Euro-Celtique S.A. Once-a-day oxycodone formulations
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE10131113A1 (en) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotary electric motor
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
HU0401344A2 (en) 2001-08-06 2004-11-29 Euro-Celtique S.A. Pharmaceutical compositions to prevent abuse of opioids and process for producing them
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1414451B1 (en) * 2001-08-06 2009-05-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
DE60231725D1 (en) 2001-09-06 2009-05-07 Hans Gregersen A balloon catheter system for stimulation and measuring the reaction produced by stimulated
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
JP2005512965A (en) 2001-09-24 2005-05-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Useful anticonvulsants derivatives in the treatment of restless limb syndrome and periodic limb movement disorder
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
EP1482835B1 (en) 2002-03-06 2012-09-12 Euro-Celtique S.A. Analog scale for measuring pain
CN1652752A (en) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 Naltrexone hydrochloride compositions
CN100411611C (en) 2002-04-05 2008-08-20 欧洲凯尔蒂克公司 Matrix for sustained, invariant and independent release of active compounds
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
RU2222260C1 (en) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Method for carrying out differential evaluation of functional activity degree of small intestine
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
WO2004064807A1 (en) 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
CN1767831B (en) 2003-04-08 2014-12-10 普罗热尼奇制药公司 Pharmaceutical formulations containing methylnaltrexone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP3228308A1 (en) 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
AT419836T (en) * 2004-03-30 2009-01-15 Euro Celtique Sa Tamper-resistant dosage form with an adsorbent and an adverse agent
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2007111945A2 (en) 2006-03-22 2007-10-04 Trustees Of Boston University Method for management of diarrhea
AU2007240873A1 (en) 2006-04-19 2007-11-01 Jill P. Smith Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
DE202006018609U1 (en) 2006-08-29 2007-05-16 Euro-Celtique S.A. Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
PE04222011A1 (en) 2008-07-07 2011-07-01 Euro Celtique Sa pharmaceutical composition comprising opioid antagonists
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2012020097A2 (en) 2010-08-13 2012-02-16 Euro-Celtique S.A. Use of binders for manufacturing storage stable formulations

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5767125A (en) * 1992-09-21 1998-06-16 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6387404B2 (en) * 1993-11-23 2002-05-14 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6627635B2 (en) * 1997-12-22 2003-09-30 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US9474750B2 (en) 1997-12-22 2016-10-25 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8936808B1 (en) 1997-12-22 2015-01-20 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9084729B2 (en) 2001-05-11 2015-07-21 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US20110135731A1 (en) * 2001-05-11 2011-06-09 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9056051B2 (en) 2001-05-11 2015-06-16 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US7276250B2 (en) 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US20030129230A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20070134328A1 (en) * 2001-07-06 2007-06-14 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US20070098794A1 (en) * 2001-07-06 2007-05-03 Haui-Hung Kao Oxymorphone controlled release formulations
US20030129234A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone
US8309122B2 (en) 2001-07-06 2012-11-13 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US20070140975A1 (en) * 2001-09-26 2007-06-21 Penwest Pharmaceuticals Co. Opioid formulations having reduced potential for abuse
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8846090B2 (en) * 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US20120183612A1 (en) * 2002-04-05 2012-07-19 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20110014280A1 (en) * 2002-09-20 2011-01-20 Garth Boehm Sequestering subunit and related compositions and methods
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US20040131552A1 (en) * 2002-09-20 2004-07-08 Alpharma, Inc. Sequestering subunit and related compositions and methods
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US20110027455A1 (en) * 2002-09-20 2011-02-03 Garth Boehm Sequestering subunit and related compositions and methods
US20060104909A1 (en) * 2002-09-23 2006-05-18 Farid Vaghefi Abuse-resistant pharmaceutical compositions
US8623412B2 (en) 2002-09-23 2014-01-07 Elan Pharma International Limited Abuse-resistant pharmaceutical compositions
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US20090238868A1 (en) * 2003-04-08 2009-09-24 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US8703186B2 (en) 2003-04-08 2014-04-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US20100098771A1 (en) * 2003-04-08 2010-04-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8425933B2 (en) 2003-04-08 2013-04-23 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US20060198881A1 (en) * 2003-04-30 2006-09-07 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20070207089A1 (en) * 2004-03-30 2007-09-06 Osvaldo Abreu Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent
US9795681B2 (en) 2004-03-30 2017-10-24 Purdue Pharma L.P. Tamper resistant dosage form comprising an adsorbent and an adverse agent
US8298579B2 (en) 2004-03-30 2012-10-30 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
US20120172387A1 (en) * 2004-06-08 2012-07-05 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US20070185147A1 (en) * 2004-06-08 2007-08-09 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US20060130828A1 (en) * 2004-12-20 2006-06-22 Sexton Douglas A Method for making a pharmaceutically active ingredient abuse-prevention device
US7827983B2 (en) 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
US20140031382A1 (en) * 2005-02-28 2014-01-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
US20120225901A1 (en) * 2005-02-28 2012-09-06 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US20090162450A1 (en) * 2006-06-19 2009-06-25 Alpharma Pharmaceuticals, Llc. Pharmaceutical composition
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US20080233197A1 (en) * 2006-06-19 2008-09-25 Francis Joseph Matthews Pharmaceutical compositions
US20100143483A1 (en) * 2006-06-19 2010-06-10 Alpharma Pharmaceuticals, Llc. Pharmaceutical compositions
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846086B2 (en) 2006-08-25 2014-09-30 Purdue Pharma L.P. Tamper resistant dosage forms
US8894988B2 (en) 2006-08-25 2014-11-25 Purdue Pharma L.P. Tamper resistant dosage forms
US8894987B2 (en) 2006-08-25 2014-11-25 William H. McKenna Tamper resistant dosage forms
US8911719B2 (en) 2006-08-25 2014-12-16 Purdue Pharma Lp Tamper resistant dosage forms
US10076499B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US10076498B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US9775810B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775811B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US8834925B2 (en) 2006-08-25 2014-09-16 Purdue Pharma L.P. Tamper resistant dosage forms
US8821929B2 (en) 2006-08-25 2014-09-02 Purdue Pharma L.P. Tamper resistant dosage forms
US9775812B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775809B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775808B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9763933B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9763886B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9084816B2 (en) 2006-08-25 2015-07-21 Purdue Pharma L.P. Tamper resistant dosage forms
US8815289B2 (en) 2006-08-25 2014-08-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9095615B2 (en) 2006-08-25 2015-08-04 Purdue Pharma L.P. Tamper resistant dosage forms
US9095614B2 (en) 2006-08-25 2015-08-04 Purdue Pharma L.P. Tamper resistant dosage forms
US9545380B2 (en) 2006-08-25 2017-01-17 Purdue Pharma L.P. Tamper resistant dosage forms
US9101661B2 (en) 2006-08-25 2015-08-11 Purdue Pharma L.P. Tamper resistant dosage forms
US9492390B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492393B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492389B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9770416B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9492392B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492391B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9486412B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9486413B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9770417B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9370512B2 (en) 2006-08-30 2016-06-21 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9763931B2 (en) 2006-08-30 2017-09-19 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9861628B2 (en) 2006-08-30 2018-01-09 Rhodes Pharmaceuticals L.P. Buprenorphine-wafer for drug substitution therapy
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8920833B2 (en) 2007-12-17 2014-12-30 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8691270B2 (en) 2007-12-17 2014-04-08 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20090175937A1 (en) * 2007-12-17 2009-07-09 Labopharm, Inc. Misuse Preventative, Controlled Release Formulation
US8920834B2 (en) 2007-12-17 2014-12-30 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
US8460640B2 (en) 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
US20110237615A1 (en) * 2008-12-12 2011-09-29 Paladin Labs Inc. Narcotic Drug Formulations with Decreased Abuse Potential
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8927013B2 (en) 2008-12-16 2015-01-06 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8685447B2 (en) 2008-12-16 2014-04-01 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20100239662A1 (en) * 2008-12-16 2010-09-23 Miloud Rahmouni Misuse preventative, controlled release formulation
US8927014B2 (en) 2008-12-16 2015-01-06 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US8987291B2 (en) 2008-12-31 2015-03-24 Upsher Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US9456985B2 (en) 2009-09-17 2016-10-04 Upsher-Smith Laboratories, Inc. Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EA032013B1 (en) * 2013-10-31 2019-03-29 Сайма Лэбс Инк. Immediate release abuse-deterrent granulated dosage forms
WO2015066172A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms

Also Published As

Publication number Publication date
JP5765820B2 (en) 2015-08-19
JP2015155467A (en) 2015-08-27
US20130172382A1 (en) 2013-07-04
US9084729B2 (en) 2015-07-21
US20140135355A1 (en) 2014-05-15
ES2361148T3 (en) 2011-06-14
JP5977784B2 (en) 2016-08-24
US9511066B2 (en) 2016-12-06
US20150258088A1 (en) 2015-09-17
US20150258087A1 (en) 2015-09-17
JP2009102405A (en) 2009-05-14
AT493130T (en) 2011-01-15
DE60238756D1 (en) 2011-02-10
US20140194456A1 (en) 2014-07-10
JP6203782B2 (en) 2017-09-27
US9283221B2 (en) 2016-03-15
US9168252B2 (en) 2015-10-27
US20160263106A1 (en) 2016-09-15
JP2018080209A (en) 2018-05-24
AU2002305559B2 (en) 2008-04-03
US20170014405A1 (en) 2017-01-19
US20120252832A1 (en) 2012-10-04
US9345701B1 (en) 2016-05-24
JP2012246319A (en) 2012-12-13
JP2005515152A (en) 2005-05-26
US20080069881A1 (en) 2008-03-20
US20180169090A1 (en) 2018-06-21
AU2008202967A1 (en) 2008-07-31
WO2002092060A1 (en) 2002-11-21
US20190111051A1 (en) 2019-04-18
CA2446550C (en) 2012-03-06
US9161937B2 (en) 2015-10-20
US9480685B2 (en) 2016-11-01
JP2016222732A (en) 2016-12-28
US20160256456A1 (en) 2016-09-08
EP1387673B1 (en) 2010-12-29
US20160008351A1 (en) 2016-01-14
AU2008202967B2 (en) 2011-09-22
US20170014406A1 (en) 2017-01-19
EP1387673A1 (en) 2004-02-11
JP2014167033A (en) 2014-09-11
US9283216B2 (en) 2016-03-15
CA2446550A1 (en) 2002-11-21
CN1525851A (en) 2004-09-01
US20140107146A1 (en) 2014-04-17
US20180185353A1 (en) 2018-07-05
US9358230B1 (en) 2016-06-07
JP4522652B2 (en) 2010-08-11
US20160151353A1 (en) 2016-06-02
US20160008346A1 (en) 2016-01-14
US8969369B2 (en) 2015-03-03
US9056051B2 (en) 2015-06-16
US20160151354A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US8337888B2 (en) Pharmaceutical formulation containing gelling agent
US7214385B2 (en) Pharmaceutical formulation containing dye
US8932630B1 (en) Opioid agonist/antagonist combinations
JP4755810B2 (en) Pharmaceutical formulations containing oxycodone and naloxone
ES2326794T3 (en) Formulations of opioid agonists with releasable and sequestered antagonist.
DK2277521T3 (en) Oral opioid agonist formulations tamper-proof
AU2007220456B2 (en) Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
ES2692437T3 (en) resistant drug abuse, method of use and method of preparation
US8486449B2 (en) Misuse preventative, controlled release formulation
US20070190142A1 (en) Dosage forms for the delivery of drugs of abuse and related methods
US20030118641A1 (en) Abuse-resistant sustained-release opioid formulation
DE60216078T2 (en) Opioid-containing dosage form against abuse
US8758825B2 (en) Sequestered antagonist formulations
AU2002309885B2 (en) Abuse resistant pharmaceutical composition containing capsaicin
ES2344350T3 (en) pharmaceutical combinations of hydrocodone and naltrexone.
US8017148B2 (en) Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
US9474750B2 (en) Opioid agonist/opioid antagonist/acetaminophen combinations
US7842307B2 (en) Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7144587B2 (en) Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20080085304A1 (en) Robust sustained release formulations
AU2002319774B2 (en) Compositions and methods to prevent abuse of opioids
ES2637338T3 (en) Methods and compositions for deter abuse of dosage forms containing opioids
US20030092724A1 (en) Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US20140112980A1 (en) Abuse-resistant pharmaceutical compositions
CA2455420A1 (en) Compositions and methods to prevent abuse of opioids

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENDO PHARMACEUTICALS, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARUSO, FRANK S.;KAO, HUAI-HUNG;REEL/FRAME:012895/0330

Effective date: 20020509

AS Assignment

Owner name: PURDUE PHARMA, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:032207/0554

Effective date: 20131029

AS Assignment

Owner name: PURDUE PHARMA L.P., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PURDUE PHARMA;REEL/FRAME:032829/0655

Effective date: 20140505